Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61), Briefing.com reports. The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $9.55 earnings per share.

Regeneron Pharmaceuticals Trading Up 2.3 %

REGN stock traded up $13.59 during trading on Friday, reaching $603.59. 145,285 shares of the stock were exchanged, compared to its average volume of 739,904. The business has a 50 day moving average price of $628.85 and a 200-day moving average price of $714.29. Regeneron Pharmaceuticals has a 1 year low of $525.99 and a 1 year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $65.99 billion, a price-to-earnings ratio of 15.79, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on REGN shares. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Bernstein Bank dropped their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. Finally, Guggenheim reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a research note on Thursday. One research analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $892.60.

Institutional Trading of Regeneron Pharmaceuticals

A hedge fund recently raised its stake in Regeneron Pharmaceuticals stock. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 261.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 948 shares of the biopharmaceutical company's stock after acquiring an additional 686 shares during the quarter. Brighton Jones LLC's holdings in Regeneron Pharmaceuticals were worth $675,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.